Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy

NCT04524390 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04524390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 8, 2021
Completion date
February 7, 2024
Enrollment
75 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

biliary atresia